

May 1, 2008

APA DSM-V Work Group Member

Name, Degree: Richard B. Krueger, M.D.
 Role(s) in Work Group: Member, Sexual and Gender Identity Disorders Work Group
 Institutional Affiliation(s): New York State Psychiatric Institute; Columbia University
Department of Psychiatry
 City, State: New York, NY

Biographical Sketch:

Dr. Krueger a psychiatrist and Medical Director of the Sexual Behavior Clinic at New York State Psychiatric Institute. He is an Associate Clinical Professor of Psychiatry in the Department of Psychiatry, Columbia University, College of Physicians and Surgeons. He received his B.A. degree from Albion College in 1967 and his M.D. degree from Harvard Medical School in 1977. He is board certified in internal medicine, psychiatry, forensic psychiatry, and addiction psychiatry. He consults on individuals who have committed sexual crimes for the New York State Office of Mental Health and his research interests and publications have focused on the psychopharmacological treatment of aggressive and compulsive sexual behavior.

UNCOMPENSATED AFFILIATIONS WITH NON-PROFIT OR ADVOCACY ORGANIZATIONS THAT MAY HAVE A DIRECT OR INDIRECT INTEREST IN PSYCHIATRIC DIAGNOSIS, TREATMENT, OR THE DSM-V : CALENDAR YEARS 2005, 2006, 2007, AND FOR 2008, ACTIVITIES TO DATE AND COMMITMENTS FOR REMAINDER OF YEAR.

Non-Profit and Advocacy Organizations	Year(s)	Role
The New York State Association for the Treatment of Sexual Abusers	2005-present	Vice-president & board member

The two tables below represent Dr. Krueger’s disclosure of significant interests and affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of the year.

Dr. Krueger has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

<p>KEY NUMBER:</p> <p>1. Consultation Fees (include scientific advisory boards)</p> <p>2. Full- or Part-time Employee</p> <p>3. Industry-related Grant-Research Support received or pending</p> <p>4. Honoraria (includes Speakers’ Bureau)</p> <p>5. Stock or other financial options</p>	<p>6. Expert testimony</p> <p>7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)</p> <p>8. Patents received or pending</p> <p>9. Officer, director/trustee, executive (specify)</p> <p>10. Other (specify)</p>
---	--

UPDATED 4.28.08

DISCLOSURE OF SIGNIFICANT INTERESTS FOR 2005, 2006, AND 2007

Commercial or Other Organization	Year(s)	Key #(s)
Johnson & Johnson	2005, 2006, 2007	5, 5, 5
Pfizer, Inc	2005, 2006, 2007	5, 5, 5
GlaxoSmithKline	2005, 2007	5, 1
Schering Plough	2005	5
Amgen, Inc.	2005, 2006, 2007	5, 5, 5
Biogen Idec, Inc.	2005, 2006, 2007	5, 5, 5
Genetech, Inc.	2005, 2006, 2007	5, 5, 5
Sanofi Aventis	2005	5

DISCLOSURE OF SIGNIFICANT INTERESTS TO DATE FOR 2008 AND COMMITMENTS FOR REMAINDER OF YEAR

Commercial or Other Organization	Year(s)	Key #(s)
None		